Abstract
Unhealthy alcohol users are much more likely than the general population to have concurrent tobacco and illicit drug use. This chapter gives an overview of what clinicians need to know about recognizing other drug use and its attendant comorbidities, and providing preventive care and substance use interventions. Substance use is most likely to be uncovered through routine screening, which should be followed by an assessment that determines the degree and severity of use. Medical providers should be aware of common medical and psychiatric problems among tobacco and other drug users. They should be prepared to provide focused preventive care, and to educate patients on harm reduction strategies, including use of sterile injection equipment and overdose prevention. Importantly, medical providers can intervene directly to help patients reduce or stop using tobacco and other drugs, through pharmacotherapy coupled with counseling. Addressing tobacco and other drug use among patients with unhealthy alcohol use can enhance the success of alcohol interventions, and improve overall patient care by helping the provider to identify and treat associated medical conditions, avoid potentially harmful drug interactions, understand and improve adherence to treatment, and build trust.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Mokdad AH, Marks JS, Stroup DF, Gerberding JL. Actual causes of death in the United States, 2000. JAMA. 2004;291:1238–45.
Neumark YD, Van Etten ML, Anthony JC. Drug dependence and death: survival analysis of the Baltimore ECA sample from 1981–1995. Sust Use Misuse. 2000;35:313–27.
Robert Wood Johnson Foundation and Schneider Institute for Health Policy. Substance abuse: the nation’s number one health problem. Princeton: Robert Wood Johnson Foundation; 2001. http://www.rwjf.org/files/publications/other/SubstanceAbuseChartbook.pdf. Accessed 5 May 2011.
Centers for Disease Control and Prevention. Unintentional poisoning deaths--United States, 1999–2004. MMWR Morbid Mortal Wkly Rep. 2007;56:93–96.
Center for Substance Abuse Research (CESAR). Unintentional drug overdose deaths continue to increase; now second leading cause of unintentional deaths. CESAR Fax. 2011;20(19).
Substance Abuse and Mental Health Services Administration. Results from the 2009 National Survey on Drug Use and Health: National Findings. RockvilleMD: Office of Applied Studies, NSDUH Series H-38 A, HHS Publication No. SMA 10–4856Findings), 2010. http://oas.samhsa.gov/NSDUH/2k9NSDUH/2k9Results.htm #7.3.2. Accessed 5 May 2011.
Whitlock EP, Polen MR, Green CA, Orleans T, Klein J. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140:557–68.
Solberg LI, Maciosek MV, Edwards NM. Primary care intervention to reduce alcohol misuse, ranking its health impact and cost effectiveness. Am J Prev Med. 2008;34:143–52.
Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alc Depend. 2009;99:280–95.
Laine C, Hauck WW, Gourevitch MN, Rothman J, Cohen A, Turner BJ. Regular outpatient medical and drug abuse care and subsequent hospitalization of persons who use illicit drugs. JAMA. 2001;285:2355–62.
Weisner C, Mertens J, Parthasarathy S, Moore C, Lu Y. Integrating primary medical care with addiction treatment: a randomized controlled trial. JAMA. 2001;286:1715–23.
O’Connor PG, Selwyn PA, Schottenfeld RS. Medical care for injection-drug users with human immunodeficiency virus infection. N Engl J Med. 1994;331:450–9.
Samet JH, Friedmann P, Saitz R. Benefits of linking primary medical care and substance abuse services: patient, provider, and societal perspectives. Arch Intern Med. 2001;161(1):85–91.
Institute of Medicine. Improving the quality of health care for mental and substance-use conditions. Washington, DC: National Academies Press; 2006.
Scott CK, Dennis ML, Laudet A, Funk RR, Simeone RS. Surviving drug addiction: the effect of treatment. Am J Public Health. 2011;737–44.
National Institutes of Health, National Institute on drug abuse. Strategic Plan; 2009. http://www.drugabuse.gov/StrategicPlan/StratPlan09/Index.html. Accessed 5 May 2011.
Kuehn BM. Treatment given high priority in new white house drug control policy. JAMA. 2010;303:821–22.
Agency for Healthcare Research and Quality. Helping smokers quit: a guide for clinicians. http://www.ahrq.gov/clinic/tobacco/clinhlpsmksqt.htm. Accessed 5 May 2011.
Smith PC, Schmidt SM, Allensworth-Davies D, Saitz R. A single-question screening test for drug use in primary care. Arch Intern Med. 2010;170:1155–60.
Brown RL, Rounds LA. Conjoint screening questionnaires for alcohol and other drug abuse: criterion validity in a primary care practice. Wis Med J. 1995;94:135–40.
Substance Abuse and Mental Health Services Administration (SAMHSA). Coding for SBI Reimbursement. http://www.samhsa.gov/prevention/SBIRT/coding.aspx. Accessed 5 May 2011.
Knight JR, Shrier LA, Bravender TD, Farrell M, Vander Bilt J, Shaffer HJ. A new brief screen for adolescent substance abuse. Arch Pediatr Adolesc Med. 1999;153:591–6.
National Institute on Drug Abuse (NIDA). Screening for drug use in general medical settings: a resource guide for providers. http://www.drugabuse.gov/nidamed/resguide/resourceguide.pdf. Accessed 14 May 2011.
Humeniuk R. Validation of the Alcohol, Smoking and substance involvement screening test (ASSIST) and pilot brief intervention: A technical report of phase II findings of the WHO ASSIST Project. World Health Organization; 2008. http://www.who.int/substance_abuse/activities/assist_technicalreport_phase2_final.pdf.) Accessed 14 May 2011.
Join Together. Drug screening.org questionnaire. http://www.drugscreening.org/about.aspx. Accessed 14 May 2011.
National Institute on Drug Abuse (NIDA). NIDA Quick Screen: Clinician’s screening tool for drug use in general medical settings. http://ww1.drugabuse.gov/nmassist/. Accessed 14 May 2011.
Merrill JO, Rhodes LA, Deyo RA, Marlatt GA, Bradley KA. Mutual mistrust in the medical care of drug users: the keys to the ‘narc’ cabinet. J Gen Intern Med. 2002;17:327–33.
The National Center on Addiction and Substance Abuse (CASA) at Columbia University. Missed opportunity: National survey of primary care physicians and patients on substance abuse. April 2004. http://www.casacolumbia.org/articlefiles/380-Missed%20Opportunity%20Physicians%20and%20Patients.pdf. Accessed 5 May 2011.
Mertens JR, Lu YW, Parthasarathy S, Moore C, Weisner CM. Medical and psychiatric conditions of alcohol and drug treatment patients in an HMO. Arch Intern Med. 2003;163:2511–7.
Mertens JR, Weisner C, Ray GT, Fireman B, Walsh K. Hazardous drinkers and drug users in HMO primary care: prevalence, medical conditions, and costs. Alcohol Clin Exp Res. 2005;29:989–98.
Devlin RJ, Henry JA. Clinical review: major consequences of illicit drug consumption. Crit Care. 2008;12(1):202. (Epub 8 Jan. 2008)
Compton WM, Thomas YF, Stinson FS, et al. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Arch Gen Psychiatry. 2007;64:566–76.
Pelucchi C, et al. Cancer risk associated with alcohol and tobacco use: focus on upper aero-digestive tract and liver. Alcohol Res Health: J Nat Inst Alcohol Abuse Alcohol. 2006;29:193–8.
Kalman D, et al. Addressing tobacco use disorder in smokers in early remission from alcohol dependence: the case for integrating smoking cessation services in substance use disorder treatment programs. Clin Psychol Rev. 2010; 30:12–24.
Lee JD, McNeely J, Gourevitch MN. Management of associated medical conditions. In: Ruiz P, Strain E, editors. Substance abuse: a comprehensive textbook. 5th ed. Baltimore: Lippincott Williams & Wilkins; 2011 [in press ].
Substance Abuse and Mental Health Services Administration. Results from the 2006 National Survey on Drug Use and Health: National Findings. Rockville, MD: Office of Applied Studies, NSDUH Series H-32, HHS Publication No. SMA 07-4293), 2007. http://oas.samhsa.gov/NSDUH/2k6NSDUH/2k6results.cfm#Ch8. Accessed 5 May 2011.
Center for Substance Abuse Treatment. Identifying and helping patients with co-occurringsubstance use and mental disorders: a guide for primary care providers. SubstAbuse Brief Fact Sheet. 2006;4(2). http://kap.samhsa.gov/products/brochures/pdfs/saib_fall06_v4i2.pdf
Ziedonis D, Brady K. Dual Diagnosis in primary care: detecting and treating both the addiction and mental illness. Med Clin North Am. 1997;81(4):1017–36.
Epstein J, Barker P, Vorburger M, Murtha C. Serious mental illness and its co-occurrence with substance use disorders. 2002. www.oas.samhsa.gov/CoD/Cod.htm. Accessed 14 May 2011.
Center for Substance Abuse Treatment. Substance abuse treatment and domestic violence. Treatment Improvement Protocol (TIP) Series 25. Rockville: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration;1997.
McCauley JL, Danielson CK, Arnstadter AB, et al. The role of traumatic event history in non-medical use of prescription drugs among a nationally representative sample of US adolescents. J Child Psychol Psychiatry. 2010;51:84–93.
Miller BA, Downs WR, Gondoli DM. Spousal violence among alcoholic women as compared to a random household sample of women. J Stud Alcohol. 1989;50(6):533.
Centers for Disease Control and Prevention. Fact sheet: drug-associated HIV transmission continues in the United Centers for States. http://www.cdc.gov/hiv/resources/Factsheets/idu.htm. Accessed 12 August 2009.
Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med. 2006;144:705–14.
U.S. Department of Health and Human Services, Public Health Service. HIV Prevention Bulletin: Medical advice for persons who inject illicit drugs. http://www.cdcnpin.org/Reports/MedAdv.pdf. Accessed 14 May 2011.
Hall HI, Song R, Rhodes P, et al. Estimation of HIV incidence in the United States. JAMA. 2008;300:520–29.
Warner-Smith M, Darke S, Lynskey M, Hall W. Heroin overdose: causes and consequences. Addiction. 2001;96:1113–25.
Piper TM, Stancliff S, Rudenstine S, Sherman S, Nandi V, Clear A, Galea S. Evaluation of a naloxone distribution and administration program in New York City. Sub Use Misuse. 2008;43:858–70.
Fiore MC, Jaen CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical Practice Guideline. Rockville: U.S. Department of Health and Human Services, Public Health Service; 2008. http://www.surgeongeneral.gov/tobacco/treating_tobacco_use08.pdf. Accessed 14 May 2011.
Prochaska J, Delucchi K, Hall S. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. J Consult Clin Psychol. 2004;72:1144–56.
Joseph A, et al. A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment. J Stud Alcohol. 2004;65:681–91.
Fiore MC, JC, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Quick reference guide for clinicians. Rockville: U.S. Department of Health and Human Services, Public Health Service; 2008.
Cooney N, et al. Smoking cessation during alcohol treatment: a randomized trial of combination nicotine patch plus nicotine gum. Addiction. 2009;104:1588–96.
Gunnell D, Wise L, Davies C, Martin RM. Varenicline and suicidal behaviour: a cohort study based on data from the General Practice Research Database. Br Med J. 2009;339:b3805.
Hays JT, et al. Varenicline for tobacco dependence treatment in recovering alcohol-dependent smokers: an open-label pilot study. J Subst Abuse Treatment. 2011;40:102–7.
Center for Substance Abuse Treatment. A guide to substance abuse services for primary care clinicians. Treatment Improvement Protocol (TIP) Series 24. Rockville: U.S. Department of Health and Human Services, Substance Abuse and Mental Health Services Administration; 1997. http://www.ncbi.nlm.nih.gov/books/NBK14386/. Accessed 14 May 2011.
Whitlock EP, Polen MR, Green CA, Orleans T, Klein J. Behavioral counseling interventions in primary care to reduce risky/harmful alcohol use by adults: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2004;140:557–68.
Solberg LI, Maciosek MV, Edwards NM. Primary care intervention to reduce alcohol misuse, ranking its health impact and cost effectiveness. Am J Prev Med. 2008;34(2):143–52.
Kaner EFS, Beyer F, Dickinson HO, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev. 2007;(2)CD004148.
Madras BK, Compton WM, Avula D, Stegbauer T, Stein JB, Clark HW. Screening, brief interventions, referral to treatment (SBIRT) for illicit drug and alcohol use at multiple healthcare sites: comparison at intake and 6 months later. Drug Alc Depend. 2009;99(1–3):280–95.
Bernstein J, Bernstein E, Tassiopoulos K, Heeren T, Levenson S, Hingson R. Brief motivational intervention at a clinic visit reduces cocaine and heroin use. Drug Alcohol Depend. 2005;77:49–59.
World Health Organization. The effectiveness of a brief intervention for illicit drugs linked to the alcohol, smoking, and substance involvement screening test (ASSIST) in primary health care settings: a technical report of phase III findings of the WHO ASSIST randomized controlled trial. World Health Organization; 2008. http://www.who.int/substance_abuse/activities/assist_technicalreport_phase3_final.pdf. Accessed 14 May 2011.
Saitz R, Alford DP, Bernstein J, Cheng DM, Samet J, Palfai T. Screening and brief intervention for unhealthy drug use in primary care settings: randomized clinical trials are needed. J Addict Med. 2010;4:123–30.
Coups EJ, Gaba A, Orleans CT. Physician screening for multiple behavioral health risk factors. Am J Prevent Med. 2004;27(S1):34–41.
Institute of Medicine. Primary care: America’s health in a new era. Washington, DC: National Academy Press; 1996.
National Quality Forum. National voluntary consensus standards for the treatment of substance use conditions: evidence-based treatment practices. Washington, DC: National Quality Forum; 2007.
Institute of Medicine. Federal regulation of methadone treatment. In: Rettig RA, Yarmolinsky A, editors. Washington, DC: National Academy Press; 1995.
Institute of Medicine. Treating drug problems, Vol. 1. In Gerstein DR, Harwood HJ, editors. Washington, DC: National Academy Press; 1990.
Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin Pharmacol Ther. 1994;55:569–80.
O’Connor PG, Oliveto AH, Shi JM, et al. A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic. Am J Med. 1998;105:100–5.
Substance Abuse and Mental Health Services Administration. The SAMHSA evaluation of the impact of the DATA Waiver Program: final summary report. Rockville: Center for Substance Abuse Treatment, US Dept. of Health and Human Services; 2006. www.buprenorphine.samhsa.gov/FOR_FINAL_summaryreport_colorized.pdf. Accessed 14 May 2011.
Alford DP, LaBelle CT, Richardson JM, et al. Treating homeless opioid dependent patients with buprenorphine in an office-based setting. J Gen Intern Med. 2007;22:171–6.
Kosten TR, Morgan C, Kosten TA. Depressive symptoms during buprenorphine treatment of opioid abusers. J Sub Abuse Treatment. 1990;7:51–54.
Center for Substance Abuse Treatment (CSAT) Buprenorphine Information Center. http://www.buprenorphine.samhsa.gov/. Accessed 14 May 2011.
Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011;4:CD001333.
Sullivan MA, Vosburg SK, Comer SD. Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology (Berl). 2006;189:37–46.
Comer SD, Sullivan MA, Yu E, Rothenberg JL, Kleber HD, Kampman K, Dackis C, O’Brien CP. Injectable, sustained-release naltrexone for the treatment of opioid dependence: a randomized, placebo-controlled trial. Arch Gen Psychiatry. 2006;63:210–8.
Krupitsky E, Nunes EV, Ling W, Illepereuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomized trial. Lancet. 2011;377:1506–13.
Substance Abuse and Mental Health Services Administration Center for Substance Abuse Treatment (CSAT). Clinical guidelines for the use of buprenorphine in the treatment of opioid addiction: substance abuse and mental health services administration; 2004.
O’Connor PG, Nyquist JG, McLellan AT. Integrating addiction medicine into graduate medical education in primary care: the time has come. Ann Int Med. 2011;154:56–59.
Pincus HA, Spaeth-Rublee B, Watkins KE. The case for measuring quality in mental health and substance abuse care. Health Affairs. 2011;30:730–36.
Croghan TW, Brown JD. Integrating mental health treatment into the patient centered medical home. (prepared by Mathematica Policy Research under Contract No. HHSA290200900019ITO2.) AHRQ Publication No. 10–0084-EF. Rockville: Agency for Healthcare Research and Quality; 2010.
Institute of Medicine. Improving the quality of health care for mental and substance-use conditions. Washington, DC: National Academies Press; 2006.
Lanier D and Ko S. Screening in primary care settings for illicit drug use: assessment of screening instruments—a supplemental evidence update for the U.S. Preventive Services Task Force. Evid Synth. 2008;58(2):1–13 (AHRQ).
Skinner HA. The drug abuse screening test. Addict Behav. 1982;7:363–7.
Berman AH, Bergman H, Palmstierna T, Schlyter F. Evaluation of the Drug Use Disorders Identification Test (DUDIT) in criminal justice and detoxification settings and in a swedish population sample. Eur Addict Res. 2005;11:22–31.
Tran N. Treating tobacco addiction. City Health Inf. 2010;29(suppl 3):1–8. http://www.nyc.gov/html/doh/downloads/pdf/chi/chi29-suppl3.pdf. Accessed 3 June 2011.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2013 Springer Science+Business Media New York
About this chapter
Cite this chapter
McNeely, J., Lee, J., Grossman, E. (2013). Other Drug Use. In: Saitz, R. (eds) Addressing Unhealthy Alcohol Use in Primary Care. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-4779-5_12
Download citation
DOI: https://doi.org/10.1007/978-1-4614-4779-5_12
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-4778-8
Online ISBN: 978-1-4614-4779-5
eBook Packages: MedicineMedicine (R0)